Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study.
Lupus Sci Med
; 9(1)2022 09.
Article
em En
| MEDLINE
| ID: mdl-36167483
ABSTRACT
OBJECTIVE:
It is still unclear how glucocorticoids (GCs) affect the long-term clinical course of patients with SLE. The objective of this study is to explore the factors associated with GC-free treatment status.METHODS:
Using data from the lupus registry of nationwide institutions, GC dose at registration was compared between short, middle and long disease durations of <5, 5-20 and ≥20 years, respectively. After excluding patients who never used GC, we evaluated the relationship between GC-free status and chronic damage using Systemic Lupus International Collaborating Clinics Damage Index.RESULTS:
GC doses at enrolment of the 1019 patients were as follows GC-free in 101 (10%); 0<prednisolone (PSL) ≤5 mg/day in 411 (40%); 5CONCLUSION:
Even in the patients with long disease duration, one-point GC-free treatment status might be related to no chronic damage accrual.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Lúpus Eritematoso Sistêmico
Tipo de estudo:
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Lupus Sci Med
Ano de publicação:
2022
Tipo de documento:
Article